Antiandrogens
Aspirin
Bamlanivimab
Bromhexine
Budesonide
Casirivimab/i..
Colchicine
Conv. Plasma
Curcumin
Favipiravir
Fluvoxamine
Hydroxychloro..
Iota-carragee..
Ivermectin
Melatonin
Metformin
Molnupiravir
Nigella Sativa
Nitazoxanide
Paxlovid
Povidone-Iod..
Probiotics
Proxalutamide
Quercetin
Remdesivir
Sotrovimab
Vitamin A
Vitamin C
Vitamin D
Zinc

Other
Feedback
Home
Top
Summary
All studies
Mortality
Ventilation
ICU
Hospitalization
Serious outcomes
Recovery
Viral clearance
RCTs
RCT mortality
Peer-reviewed
All outcomes

Feedback
Home   COVID-19 treatment studies for Nitazoxanide  COVID-19 treatment studies for Nitazoxanide  C19 studies: Nitazoxanide  Nitazoxanide   Select treatmentSelect treatmentTreatmentsTreatments
Antiandrogens (meta) Metformin (meta)
Aspirin (meta) Molnupiravir (meta)
Bamlanivimab (meta) Nigella Sativa (meta)
Bromhexine (meta) Nitazoxanide (meta)
Budesonide (meta) Paxlovid (meta)
Casirivimab/i.. (meta) Povidone-Iod.. (meta)
Colchicine (meta) Probiotics (meta)
Conv. Plasma (meta) Proxalutamide (meta)
Curcumin (meta) Quercetin (meta)
Favipiravir (meta) Remdesivir (meta)
Fluvoxamine (meta) Sotrovimab (meta)
Hydroxychloro.. (meta) Vitamin A (meta)
Iota-carragee.. (meta) Vitamin C (meta)
Ivermectin (meta) Vitamin D (meta)
Melatonin (meta) Zinc (meta)

Other Treatments Global Adoption
Outcomes in COVID-19 nitazoxanide studies
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ All studies 55% 6 1,464 Improvement, Studies, Patients Relative Risk, 95% CI Mortality 60% 3 923 Ventilation 85% 2 544 ICU admission -404% 1 392 Hospitalization 71% 4 1,315 Recovery -16% 1 392 Viral clearance 60% 4 583 RCTs 25% 4 857 Peer-reviewed 73% 4 1,049 Early 49% 5 1,414 Late 67% 1 50 Nitazoxanide for COVID-19 c19nitazoxanide.com Dec 3, 2021 Favors nitazoxanide Favors control
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Rocco (RCT) -404% 5.04 [0.24-104] ICU 2/194 0/198 Improvement, RR [CI] Treatment Control Cadegiani 88% 0.12 [0.01-2.52] death 0/357 2/137 Elalfy 87% 0.13 [0.06-0.27] viral+ 7/62 44/51 CT​1 Silva (SB RCT) 26% 0.74 [0.38-1.41] viral+ 23 (n) 13 (n) Rossignol (DB RCT) -206% 3.06 [0.13-74.6] death 1/184 0/195 Tau​2 = 1.35; I​2 = 77.4% Early treatment 49% 0.51 [0.13-1.95] 10/820 46/594 49% improvement Blum (DB RCT) 67% 0.33 [0.07-1.50] death 2/25 6/25 Improvement, RR [CI] Treatment Control Tau​2 = 0.00; I​2 = 0.0% Late treatment 67% 0.33 [0.07-1.50] 2/25 6/25 67% improvement All studies 55% 0.45 [0.15-1.35] 12/845 52/619 55% improvement 6 nitazoxanide COVID-19 studies c19nitazoxanide.com Dec 3, 2021 1 CT: study uses combined treatmentTau​2 = 1.03; I​2 = 71.7%; Z = 1.42 Effect extraction pre-specified Favors nitazoxanide Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Cadegiani 88% 0.12 [0.01-2.52] 0/357 2/137 Improvement, RR [CI] Treatment Control Rossignol (DB RCT) -206% 3.06 [0.13-74.6] 1/184 0/195 Tau​2 = 2.67; I​2 = 51.4% Early treatment 41% 0.59 [0.02-13.8] 1/541 2/332 41% improvement Blum (DB RCT) 67% 0.33 [0.07-1.50] 2/25 6/25 Improvement, RR [CI] Treatment Control Tau​2 = 0.00; I​2 = 0.0% Late treatment 67% 0.33 [0.07-1.50] 2/25 6/25 67% improvement All studies 60% 0.40 [0.10-1.58] 3/566 8/357 60% improvement 3 nitazoxanide COVID-19 mortality results c19nitazoxanide.com Dec 3, 2021 Tau​2 = 0.17; I​2 = 9.3%; Z = 1.31 Favors nitazoxanide Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Cadegiani 97% 0.03 [0.00-0.51] 0/357 9/137 Improvement, RR [CI] Treatment Control Tau​2 = 0.00; I​2 = 0.0% Early treatment 97% 0.03 [0.00-0.51] 0/357 9/137 97% improvement Blum (DB RCT) 62% 0.38 [0.11-1.25] 3/25 8/25 Improvement, RR [CI] Treatment Control Tau​2 = 0.00; I​2 = 0.0% Late treatment 62% 0.38 [0.11-1.25] 3/25 8/25 62% improvement All studies 85% 0.15 [0.01-1.62] 3/382 17/162 85% improvement 2 nitazoxanide COVID-19 mechanical ventilation results c19nitazoxanide.com Dec 3, 2021 Tau​2 = 1.96; I​2 = 61.3%; Z = 1.56 Favors nitazoxanide Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Rocco (RCT) -404% 5.04 [0.24-104] 2/194 0/198 Improvement, RR [CI] Treatment Control Tau​2 = 0.00; I​2 = 0.0% Early treatment -404% 5.04 [0.24-104] 2/194 0/198 -404% improvement All studies -404% 5.04 [0.24-104] 2/194 0/198 -404% improvement 1 nitazoxanide COVID-19 ICU result c19nitazoxanide.com Dec 3, 2021 Tau​2 = 0.00; I​2 = 0.0%; Z = 1.05 Favors nitazoxanide Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Rocco (RCT) -2% 1.02 [0.30-3.47] hosp. 5/194 5/198 Improvement, RR [CI] Treatment Control Cadegiani 99% 0.01 [0.00-0.17] hosp. 0/357 27/137 Rossignol (DB RCT) 79% 0.21 [0.02-1.80] hosp. 1/184 5/195 Tau​2 = 3.68; I​2 = 78.4% Early treatment 83% 0.17 [0.01-2.00] 6/735 37/530 83% improvement Blum (DB RCT) 56% 0.44 [0.22-0.89] hosp. time 25 (n) 25 (n) Improvement, RR [CI] Treatment Control Tau​2 = 0.00; I​2 = 0.0% Late treatment 56% 0.44 [0.22-0.89] 0/25 0/25 56% improvement All studies 71% 0.29 [0.08-1.06] 6/760 37/555 71% improvement 4 nitazoxanide COVID-19 hospitalization results c19nitazoxanide.com Dec 3, 2021 Tau​2 = 1.06; I​2 = 67.6%; Z = 1.88 Favors nitazoxanide Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Rocco (RCT) -404% 5.04 [0.24-104] ICU 2/194 0/198 Improvement, RR [CI] Treatment Control Cadegiani 88% 0.12 [0.01-2.52] death 0/357 2/137 Rossignol (DB RCT) -206% 3.06 [0.13-74.6] death 1/184 0/195 Tau​2 = 1.71; I​2 = 40.9% Early treatment -21% 1.21 [0.12-12.3] 3/735 2/530 -21% improvement Blum (DB RCT) 67% 0.33 [0.07-1.50] death 2/25 6/25 Improvement, RR [CI] Treatment Control Tau​2 = 0.00; I​2 = 0.0% Late treatment 67% 0.33 [0.07-1.50] 2/25 6/25 67% improvement All studies 31% 0.69 [0.15-3.29] 5/760 8/555 31% improvement 4 nitazoxanide COVID-19 serious outcomes c19nitazoxanide.com Dec 3, 2021 Tau​2 = 0.88; I​2 = 33.9%; Z = 0.46 Effect extraction pre-specified Favors nitazoxanide Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Rocco (RCT) -16% 1.16 [0.84-1.59] no recov. 59/194 52/198 Improvement, RR [CI] Treatment Control Tau​2 = 0.00; I​2 = 0.0% Early treatment -16% 1.16 [0.84-1.59] 59/194 52/198 -16% improvement All studies -16% 1.16 [0.84-1.59] 59/194 52/198 -16% improvement 1 nitazoxanide COVID-19 recovery result c19nitazoxanide.com Dec 3, 2021 Tau​2 = 0.00; I​2 = 0.0%; Z = 0.91 Favors nitazoxanide Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Rocco (RCT) 12% 0.88 [0.80-0.96] viral+ 194 (n) 198 (n) Improvement, RR [CI] Treatment Control Elalfy 87% 0.13 [0.06-0.27] viral+ 7/62 44/51 CT​1 Silva (SB RCT) 26% 0.74 [0.38-1.41] viral+ 23 (n) 13 (n) Tau​2 = 0.78; I​2 = 92.8% Early treatment 54% 0.46 [0.16-1.30] 7/279 44/262 54% improvement Blum (DB RCT) 90% 0.10 [0.01-1.78] viral+ 0/23 4/19 Improvement, RR [CI] Treatment Control Tau​2 = 0.00; I​2 = 0.0% Late treatment 90% 0.10 [0.01-1.78] 0/23 4/19 90% improvement All studies 60% 0.40 [0.15-1.09] 7/302 48/281 60% improvement 4 nitazoxanide COVID-19 viral clearance results c19nitazoxanide.com Dec 3, 2021 1 CT: study uses combined treatmentTau​2 = 0.79; I​2 = 89.9%; Z = 1.79 Favors nitazoxanide Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Rocco (RCT) -404% 5.04 [0.24-104] ICU 2/194 0/198 Improvement, RR [CI] Treatment Control Silva (SB RCT) 26% 0.74 [0.38-1.41] viral+ 23 (n) 13 (n) Rossignol (DB RCT) -206% 3.06 [0.13-74.6] death 1/184 0/195 Tau​2 = 0.09; I​2 = 6.3% Early treatment 8% 0.92 [0.41-2.08] 3/401 0/406 8% improvement Blum (DB RCT) 67% 0.33 [0.07-1.50] death 2/25 6/25 Improvement, RR [CI] Treatment Control Tau​2 = 0.00; I​2 = 0.0% Late treatment 67% 0.33 [0.07-1.50] 2/25 6/25 67% improvement All studies 25% 0.75 [0.36-1.55] 5/426 6/431 25% improvement 4 nitazoxanide COVID-19 Randomized Controlled Trials c19nitazoxanide.com Dec 3, 2021 Tau​2 = 0.09; I​2 = 11.3%; Z = 0.78 Effect extraction pre-specified Favors nitazoxanide Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Rossignol (DB RCT) -206% 3.06 [0.13-74.6] 1/184 0/195 Improvement, RR [CI] Treatment Control Tau​2 = 0.00; I​2 = 0.0% Early treatment -206% 3.06 [0.13-74.6] 1/184 0/195 -206% improvement Blum (DB RCT) 67% 0.33 [0.07-1.50] 2/25 6/25 Improvement, RR [CI] Treatment Control Tau​2 = 0.00; I​2 = 0.0% Late treatment 67% 0.33 [0.07-1.50] 2/25 6/25 67% improvement All studies 37% 0.63 [0.09-4.54] 3/209 6/220 37% improvement 2 nitazoxanide COVID-19 RCT mortality results c19nitazoxanide.com Dec 3, 2021 Tau​2 = 0.84; I​2 = 34.0%; Z = 0.45 Favors nitazoxanide Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Rocco (RCT) -404% 5.04 [0.24-104] ICU 2/194 0/198 Improvement, RR [CI] Treatment Control Cadegiani 88% 0.12 [0.01-2.52] death 0/357 2/137 Elalfy 87% 0.13 [0.06-0.27] viral+ 7/62 44/51 CT​1 Tau​2 = 2.14; I​2 = 62.4% Early treatment 68% 0.32 [0.04-2.58] 9/613 46/386 68% improvement Blum (DB RCT) 67% 0.33 [0.07-1.50] death 2/25 6/25 Improvement, RR [CI] Treatment Control Tau​2 = 0.00; I​2 = 0.0% Late treatment 67% 0.33 [0.07-1.50] 2/25 6/25 67% improvement All studies 73% 0.27 [0.08-0.94] 11/638 52/411 73% improvement 4 nitazoxanide COVID-19 peer reviewed trials c19nitazoxanide.com Dec 3, 2021 1 CT: study uses combined treatmentTau​2 = 0.76; I​2 = 51.1%; Z = 2.06 Effect extraction pre-specified Favors nitazoxanide Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Rocco (RCT) -404% 5.04 [0.24-104] ICU 2/194 0/198 Improvement, RR [CI] Treatment Control Rocco (RCT) -2% 1.02 [0.30-3.47] hosp. 5/194 5/198 Rocco (RCT) -16% 1.16 [0.84-1.59] no recov. 59/194 52/198 Rocco (RCT) 12% 0.88 [0.80-0.96] viral+ 194 (n) 198 (n) Rocco (RCT) 14% 0.86 [0.77-0.96] viral+ 136/194 162/198 Cadegiani 88% 0.12 [0.01-2.52] death 0/357 2/137 Cadegiani 97% 0.03 [0.00-0.51] ventilation 0/357 9/137 Cadegiani 99% 0.01 [0.00-0.17] hosp. 0/357 27/137 Elalfy 87% 0.13 [0.06-0.27] viral+ 7/62 44/51 CT​1 Elalfy 58% 0.42 [0.31-0.56] viral+ 26/62 51/51 CT​1 Silva (SB RCT) 26% 0.74 [0.38-1.41] viral+ 23 (n) 13 (n) Silva (SB RCT) 38% 0.62 [0.39-0.97] viral+ 12/23 11/13 Rossignol (DB RCT) -206% 3.06 [0.13-74.6] death 1/184 0/195 Rossignol (DB RCT) 79% 0.21 [0.02-1.80] hosp. 1/184 5/195 Rossignol (DB RCT) 85% 0.15 [0.02-1.22] severe case 1/184 7/195 Rossignol (DB RCT) 84% 0.16 [0.02-1.29] severe case 1/112 7/126 Blum (DB RCT) 67% 0.33 [0.07-1.50] death 2/25 6/25 Blum (DB RCT) 62% 0.38 [0.11-1.25] ventilation 3/25 8/25 Blum (DB RCT) 56% 0.44 [0.22-0.89] hosp. time 25 (n) 25 (n) Blum (DB RCT) 90% 0.10 [0.01-1.78] viral+ 0/23 4/19 nitazoxanide COVID-19 outcomes c19nitazoxanide.com Dec 3, 2021 Favors nitazoxanide Favors control
Please send us corrections, updates, or comments. Vaccines and treatments are both extremely valuable and complementary. All practical, effective, and safe means should be used. Elimination of COVID-19 is a race against viral evolution. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. Denying the efficacy of any method increases the risk of COVID-19 becoming endemic; and increases mortality, morbidity, and collateral damage. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. Treatment protocols for physicians are available from the FLCCC.
  or use drag and drop   
Thanks for your feedback! Please search before submitting papers and note that studies are listed under the date they were first available, which may be the date of an earlier preprint.
Submit